Cytosorbents Announces The Regulatory Approval Of Cytosorb In Taiwan For Extracorporeal Removal Of Cytokines (e.g. Cytokine Storm, Sepsis), Bilirubin (e.g. Liver Disease), And Myoglobin (e.g. Trauma) From A Patient's Circulating Blood

6/24/24 7:19:11 AM ET

Medical/Dental Instruments

Health Care

Get the next $CTSO alert in real time by email

The removal of the antithrombotic drugs Brilinta® (ticagrelor, AstraZeneca) and Xarelto® (rivaroxaban, Janssen/Bayer) during cardiothoracic surgery is also approved, with the goal of reducing perioperative bleeding. CytoSorb will be distributed throughout Taiwan by Hemoscien Corporation.

Get the next $CTSO alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$CTSO

Date	Price Target	Rating	Analyst
9/7/2023	$4.00	Buy	B. Riley Securities
10/14/2021	$10.00	Buy	B. Riley Securities

More analyst ratings

CytoSorbents Reports Third Quarter 2024 Financial and Operational Results
PRINCETON, N.J., Nov. 07, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ:CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today reported unaudited financial and operating results for the third quarter ended September 30, 2024. Third Quarter 2024 Financial Results Product revenue of $8.6 million, 11% growth versus $7.8 million in Q3 2023Total revenue of $9.4 million inclusive of product and grant revenue, 7% growth versus $8.8 million in Q3 2023Product gross margins decreased to 61%, compared to 72% in Q3 2023, reflecting the impact of a planned production slowdown to rebalance inve
11/7/24 4:05:00 PM ET
$CTSO
Medical/Dental Instruments
Health Care
CytoSorbents to Report Third Quarter 2024 Operating and Financial Results
PRINCETON, N.J., Oct. 17, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ:CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report third quarter 2024 operating and financial results after the market close on Thursday, November 7, 2024. CytoSorbents' management will host a live conference call, presentation webcast, and a question-and-answer session starting at 4:30PM ET the same day. Webcast Details:Date: Thursday, November 7, 2024Time: 4:30 PM ETLive webcast link: https://edge.media-server.com/mmc/p/e9gv3iawConference ID: 9258825 Participant Dial-In:Participant Dial-in toll-free: (80
10/17/24 7:00:00 AM ET
$CTSO
Medical/Dental Instruments
Health Care
CytoSorbents Reports Second Quarter 2024 Financial and Operational Results
New CFO Peter J. Mariani to succeed retiring CFO Kathleen P. BlochOn track for DrugSorb™-ATR U.S. FDA De Novo and Health Canada marketing submissions this quarterIn Q2 2024, increased product sales by 10% and reduced operating loss by 48%Achieved more than a quarter million CytoSorb treatments cumulatively delivered to date – a major company milestone PRINCETON, N.J., Aug. 13, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ:CTSO), a pioneer in critical care and cardiac surgery blood purification technologies, today reported unaudited financial and operating results for the quarter ended June 30, 2024. Second Quarter 2024 Financial Results Total revenue for Q2 202
8/13/24 4:19:55 PM ET
$CTSO
Medical/Dental Instruments
Health Care

CytoSorbents And Converge Biotech Announce Strategic Partnership to Expand Sepsis and Critical Care Treatment with CytoSorb in India
PRINCETON, N.J. and HYDERABAD, India, Nov. 11, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ:CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit (ICU) and during cardiac surgery through blood purification, and Converge Biotech, a prominent healthcare company with a strong critical care and infectious disease focus in India, are pleased to announce a new strategic collaboration where the two companies seek to expand their combined market reach in the sepsis and critical care markets in India with a broad synergistic product portfolio. CytoSorbents is renowned for its flagship product, CytoSorb®, a blood purification technology that red
11/11/24 7:30:00 AM ET
$CTSO
Medical/Dental Instruments
Health Care
CytoSorbents Reports Third Quarter 2024 Financial and Operational Results
PRINCETON, N.J., Nov. 07, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ:CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today reported unaudited financial and operating results for the third quarter ended September 30, 2024. Third Quarter 2024 Financial Results Product revenue of $8.6 million, 11% growth versus $7.8 million in Q3 2023Total revenue of $9.4 million inclusive of product and grant revenue, 7% growth versus $8.8 million in Q3 2023Product gross margins decreased to 61%, compared to 72% in Q3 2023, reflecting the impact of a planned production slowdown to rebalance inve
11/7/24 4:05:00 PM ET
$CTSO
Medical/Dental Instruments
Health Care
CytoSorbents Submits Health Canada Medical Device License Application for DrugSorb-ATR Following MDSAP Certification
Targets the reduction in CABG-related bleeding severity due to the blood thinning drug, ticagrelor – a major unmet medical need in heart attack patients requiring surgerySuccessful MDSAP certification confirms compliance with Health Canada and U.S. FDA quality management system requirements, replacing FDA audit and inspection if requiredHealth Canada and U.S. FDA regulatory decisions expected in 2025 PRINCETON, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ:CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced the submission of its DrugSorb™-ATR Medical Device Licen
11/4/24 7:00:00 AM ET
$CTSO
Medical/Dental Instruments
Health Care

$CTSO
Leadership Updates

Live Leadership Updates

CytoSorbents And Converge Biotech Announce Strategic Partnership to Expand Sepsis and Critical Care Treatment with CytoSorb in India
PRINCETON, N.J. and HYDERABAD, India, Nov. 11, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ:CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit (ICU) and during cardiac surgery through blood purification, and Converge Biotech, a prominent healthcare company with a strong critical care and infectious disease focus in India, are pleased to announce a new strategic collaboration where the two companies seek to expand their combined market reach in the sepsis and critical care markets in India with a broad synergistic product portfolio. CytoSorbents is renowned for its flagship product, CytoSorb®, a blood purification technology that red
11/11/24 7:30:00 AM ET
$CTSO
Medical/Dental Instruments
Health Care
CytoSorbents Appoints Peter J. Mariani Chief Financial Officer
PRINCETON, N.J., Aug. 13, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ:CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announces the appointment of Peter J. Mariani as Chief Financial Officer (CFO), effective August 14, 2024. Mr. Mariani will report to Dr. Phillip Chan, Chief Executive Officer of CytoSorbents. Concurrently, Kathleen P. Bloch, CytoSorbents' current CFO, announced her retirement from the Company effective as of the close of business today, and will continue to serve in an advisory role as a consultant to enable an effective t
8/13/24 4:18:28 PM ET
$AXGN
$CTSO
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
Medical/Dental Instruments
CytoSorbents Announces Kathleen P. Bloch To Resume as Full-Time Chief Financial Officer
PRINCETON, N.J., Sept. 19, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ:CTSO), a critical care therapy leader commercializing its CytoSorb® blood purification technology to treat cytokine storm and deadly inflammation in critically-ill and cardiac surgery patients around the world, announced the re-appointment of Kathleen P. Bloch as full-time Chief Financial Officer, effective retroactively to September 2, 2023. Ms. Bloch served as the Company's Chief Financial Officer for 10 years until her retirement in March 2023, when she became Interim CFO as a consultant. She resumed as Interim CFO after the investigation of, and mutual termination and release agreement with, former CFO
9/19/23 7:00:00 AM ET
$CTSO
Medical/Dental Instruments
Health Care

Cytosorbents Announces The Regulatory Approval Of Cytosorb In Taiwan For Extracorporeal Removal Of Cytokines (e.g. Cytokine Storm, Sepsis), Bilirubin (e.g. Liver Disease), And Myoglobin (e.g. Trauma) From A Patient's Circulating Blood

Chat with this insight

Recent Analyst Ratings for $CTSO

$CTSO Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Sobel Alan D. bought $30,001 worth of shares (22,557 units at $1.33), increasing direct ownership by 28% to 101,857 units (SEC Form 4)

Capponi Vincent bought $25,000 worth of shares (18,797 units at $1.33), increasing direct ownership by 3% to 584,134 units (SEC Form 4)

Deliargyris Efthymios bought $30,001 worth of shares (22,557 units at $1.33), increasing direct ownership by 7% to 348,433 units (SEC Form 4)

$CTSO Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Cytosorbents Corporation

SEC Form SC 13G filed by Cytosorbents Corporation

SEC Form SC 13G filed by Cytosorbents Corporation

$CTSO SEC Filings

SEC Form 10-Q filed by Cytosorbents Corporation

Cytosorbents Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

Cytosorbents Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

$CTSO Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Chief Medical Officer Deliargyris Efthymios

SEC Form 4 filed by President and COO Capponi Vincent

Chief Financial Officer Mariani Peter J was granted 350,000 shares (SEC Form 4)

$CTSO Financials

Live finance-specific insights

$CTSO Press Releases

Fastest customizable press release news feed in the world

$CTSO Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

CytoSorbents Reports Third Quarter 2024 Financial and Operational Results

CytoSorbents to Report Third Quarter 2024 Operating and Financial Results

CytoSorbents Reports Second Quarter 2024 Financial and Operational Results

CytoSorbents And Converge Biotech Announce Strategic Partnership to Expand Sepsis and Critical Care Treatment with CytoSorb in India

CytoSorbents Reports Third Quarter 2024 Financial and Operational Results

CytoSorbents Submits Health Canada Medical Device License Application for DrugSorb-ATR Following MDSAP Certification

B. Riley Securities initiated coverage on CytoSorbents with a new price target

B. Riley Securities resumed coverage on CytoSorbents with a new price target

$CTSO Leadership Updates

Live Leadership Updates

CytoSorbents And Converge Biotech Announce Strategic Partnership to Expand Sepsis and Critical Care Treatment with CytoSorb in India

CytoSorbents Appoints Peter J. Mariani Chief Financial Officer

CytoSorbents Announces Kathleen P. Bloch To Resume as Full-Time Chief Financial Officer

$CTSO Market Insights

Live Market Insights

Why CytoSorbents (CTSO) Stock Is Trading Higher

CytoSorbents shares are trading higher after the company entered into a new $20 million credit facility with Avenue Capital Group.

CytoSorbents Entered Into A New $20M Credit Facility With Avenue Capital Group

Recent Analyst Ratings for
$CTSO

$CTSO
Insider Purchases

$CTSO
Large Ownership Changes

$CTSO
SEC Filings

$CTSO
Insider Trading

$CTSO
Financials

$CTSO
Press Releases

$CTSO
Analyst Ratings

$CTSO
Leadership Updates

$CTSO
Market Insights